ストックスクリーナーアプリを入手
1.14
0.88%
0.01
前日終値:
$1.13
開ける：
$1.16
24時間の取引高:
107.47K
Relative Volume:
0.55
時価総額：
$7.93M
収益：
-
当期純損益:
$-18.68M
株価収益率:
-0.1542
EPS:
-7.3948
ネットキャッシュフロー:
$-15.70M
1週間 パフォーマンス:
-12.31%
1か月 パフォーマンス:
-37.02%
6か月 パフォーマンス:
-19.72%
1年 パフォーマンス:
-88.38%
1日の値動き範囲:
$1.12
$1.20
1週間の範囲:
$1.10
$1.32
52週間の値動き範囲:
$0.6201
$10.33
Fibrobiologics Inc Stock (FBLG) Company Profile
Compare FBLG vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.14 | 9.67M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
509.16 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
743.18 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.15 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
931.92 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.17 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-12 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-24 | 開始されました | Maxim Group | Buy |
Fibrobiologics Inc (FBLG) 最新ニュース
FibroBiologics receives European patent for fibroblast therapy - Investing.com
FibroBiologics, Inc. (FBLG) Stock Price, News, Quote & History - Yahoo! Finance Canada
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity - Morningstar
Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Eagle-Tribune
FibroBiologics (FBLG) Slips 4.90% to $1.36 as Shares Drift Toward Key SupportVanna Flow - dars.gov.et
FibroBiologics Shareholders Approve Potential Warrant-Driven Share Issuance - TipRanks
FibroBiologics (NASDAQ: FBLG) raises $0.5M in insider deal - Stock Titan
Hamid Khoja Discloses Investment at FibroBiologics with 7.5% Stake - TradingView
Private deal gives FibroBiologics (FBLG) CSO hundreds of thousands of shares - Stock Titan
FBLG: Shareholders approved new share issuances as clinical and strategic progress was highlighted - tradingview.com
FibroBiologics CSO invests $500,000 in private placement By Investing.com - Investing.com
FibroBiologics, Inc. (NASDAQ:FBLG) CSO Invests ~$0.5M in Private Placement With Warrants - TradingView
Fibrobiologics Announces Closing of $0.5 Mill - Moomoo
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer - PR Newswire
FibroBiologics (FBLG) turns to a private stock-and-warrant deal for new funding - Stock Titan
Form 8K Fibrobiologics Inc For: 15 September By Investing.com - Investing.com Nigeria
FibroBiologics Announces Insider Private Placement Financing - TipRanks
FibroBiologics (FBLG) CSO to buy new shares and warrants in private deal - Stock Titan
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications - ACCESS Newswire
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing - Yahoo Finance
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media - Morningstar
A new patent covers a way to promote repair in damaged spinal discs from FibroBiologics. - Stock Titan
About 80% of Americans experience lower back pain. FibroBiologics gets a European patent. - Stock Titan
FibroBiologics ships new batch of diabetic ulce... - Pluang
FibroBiologics ships third batch of trial drug to Australia - Investing.com
FibroBiologics ships third batch of trial drug to Australia By Investing.com - Investing.com India
FibroBiologics ships a third batch of wound treatment being tested to Australia - Stock Titan
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - PR Newswire
FibroBiologics regains Nasdaq bid price compliance - Investing.com
FibroBiologics Regains Compliance with Nasdaq Trading Rules - PR Newswire
FibroBiologics Adds Sports Agent Leigh Steinberg to Board of Directors - citybiz
FibroBiologics appoints Leigh Steinberg to board By Investing.com - Investing.com Canada
Leigh Steinberg, agent behind $4B in deals, joins FibroBiologics (FBLG) board - Stock Titan
FibroBiologics | 10-Q: Q1 2026 Earnings Report - Moomoo
FibroBiologics receives Australian patent for disc disease therapy By Investing.com - Investing.com Canada
FibroBiologics receives Australian patent for disc disease therapy - Investing.com
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease - Morningstar
FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment - Sahm
FibroBiologics reports cartilage repair in animal study By Investing.com - Investing.com South Africa
FibroBiologics reports cartilage repair in animal study - Investing.com
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints - PR Newswire
Armistice Capital discloses 9.99% FibroBiologics (FBLG) stake via Master Fund - Stock Titan
FibroBiologics Inc - Smartkarma
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances Fibroblast Pipeline - vinanet.vn
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 7.77% Share GainFinal Results - dars.gov.et
FibroBiologics receives patent for islet transplant method By Investing.com - Investing.com UK
FibroBiologics receives patent for islet transplant method - Investing.com
Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts - TradingView
FibroBiologics Patent Could Help Stretch Scarce Donor Pancreases - Stock Titan
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets - PR Newswire
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesEPS Guidance Update - dars.gov.et
Fibrobiologics Inc (FBLG) 財務データ
収益
当期純利益
現金流量
EPS
Fibrobiologics Inc (FBLG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
0.45%
1.08%
大文字化:
|
ボリューム (24 時間):